Fig. 3

HIF-1α pathway inhibitor as a therapeutic strategy for lung cancer with interstitial pneumonia (IP) A Experimental scheme of comparison of treatments in the IP + LC model. The injected cancer cells were LLC cells. O.A., oropharyngeal administration. BLM bleomycin, AsA ascorbic acid, HIF-1α hypoxia-inducible factor 1α. HIF-1α-i, HIF-1α inhibitor. HC Healthy control. B Hematoxylin and eosin staining of lung sections and macroscopic evaluation obtained from the Control, HIF-1α-i, and AsA + groups on day 28. Scale bar: 300 μm. C–E Comparison of C tumor volume, D weight of mediastinal lymph nodes, and E number of metastatic foci among the Control, HIF-1α-i, and AsA + groups on day 28 (n = 7/group). NS represents not significant. *P < 0.05, **P < 0.01. F Comparison of hydroxyproline levels among the Control, HIF-1α-i, and AsA + groups on day 28 (n = 10/group). NS represents not significant. *P < 0.05